Outlook for immune intervention in type I diabetes.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D001323:Autoantibodies / Q000096:biosynthesis; D001327:Autoimmune Diseases / Q000209:etiology / Q000276:immunology / Q000628:therapy; D003524:Cyclosporins / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D008212:Lymphocyte Depletion; D051379:Mice; D010951:Plasma Exchange; D014165:Transfer Factor / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D001323:Autoantibodies; D003524:Cyclosporins; D007166:Immunosuppressive Agents; D014165:Transfer Factor